Introduction
Cell transformation is associated with profound changes in the composition of the extracellular matrix, leading to a dramatic reduction of the major structural components through both up-regulation of proteases and down-regulation of structural components such as ®bronectin and collagens. These changes are thought to facilitate proliferation of cancer cells, as well as invasion and metastasis (Benjamin and Vogt, 1990; Hanahan and Weinberg, 2000; Jove and Hanafusa, 1987) .
In primary cultures of chick embryo ®broblasts (CEFs) overexpression of the membrane-bound v-Src or the nuclear v-Jun oncoprotein has been shown to down-regulate several of these extracellular matrixencoding genes (Vial and Castellazzi, 2000) . One of these encodes the low molecular weight glycoprotein SPARC (Secreted Protein, Acidic, and Rich in Cysteine) (Mason et al., 1986a,b; Sage et al., 1984) , also designated osteonectin (Termine et al., 1981) and BM-40 (Dziadek et al., 1986) . The SPARC protein has a ubiquitous tissue distribution and displays a high sequence conservation in vertebrates, including Xenopus, chicken, mouse, cow, and man. It interacts with many structural components of the extracellular matrix as well as with proteases and growth factors. It is thought to regulate matrix ± cell interactions (Bornstein, 1995) , but its precise function remains unclear. Changes in the level of SPARC have been associated with remodeling tissues and sites of high cellular turnover, during development, wound healing, and carcinogenesis. Although the isolation of promoter regions from cow, mouse and man has been reported, little is actually known about their control by speci®c transcription factors (Reed and Sage, 1996; Timpl and Aumailley, 1993) .
In the present study we took advantage of the repression of SPARC by v-Jun to investigate a possible general control of this extracellular matrix component by the AP1 transcription factor. Indeed, v-Jun is thought to function as a subunit of AP1 by combining with several of the various members of the Jun, Fos, ATF, and Maf families (Angel and Karin, 1991; Karin et al., 1997; Vogt, 1994) . CEFs stably transformed by v-Jun were therefore generated, and the eect of the main partners of v-Jun on the transcriptional regulation of SPARC was tested. This was done, ®rstly at the level of the endogenous gene, and secondly, on an isolated fragment of the avian promoter.
Results

Transcriptional repression of SPARC by v-Jun, and modulation by Fra2 and ATF2
We have previously shown that v-Jun and v-Jun-m1 (a mutant that exhibits enhanced tumorigenicity in vivo ) down-regulate the steady-state level of the SPARC mRNA in stably transformed CEFs (Vial and Castellazzi, 2000) . Experiments were designed to estimate the contribution of the predominant dimerization partners of v-Jun, i.e. Fra2 and ATF2 van Dam et al., 1998) , to this repression.
In a ®rst series of experiments, CEF cultures infected by the viruses R, R-Fra2, R-v-Jun, R-v-Jun-m1, and combinations of R-Fra2 and R-v-Jun(-m1), were generated. The level of SPARC mRNA was estimated by Northern blot analysis in the transformed CEFs in comparison to the non-transformed CEFs (referred to as 100%). As recently reported (Vial and Castellazzi, 2000) a clear reduction of approximately 50% and 90% was found with v-Jun and v-Jun-m1 respectively ( Figure 1a ). When overexpressed, alone and in combination with v-Jun(-m1), Fra2 also reduced the level of SPARC mRNA in all cultures. The strongest reduction was observed with v-Jun-m1+Fra2. The level of SPARC, Jun and Fra2 protein from the same cultures was also estimated by Western blot analysis followed by immunodetection of the corresponding proteins. As expected, the level of the SPARC protein paralleled the level of the transcript, the strongest repression again being observed with v-Jun-m1+Fra2 (compare Figure 1a ,b upper panel`anti-SPARC').
The reduction in the SPARC protein due to Fra2 could not be attributed to an enhanced accumulation of v-Jun(-m1), since the oncoproteins accumulated to exactly the same extent with and without Fra2 ( Figure  1b middle panel anti-Jun). (Note that the endogenous cJun was down-regulated in the various v-Jun-transformed CEF cultures as already reported by dierent groups; Gao et al., 1996; Kilbey et al., 1996.) Interestingly, the accumulation of the Fra2 protein itself was signi®cantly higher with v-Jun and v-Jun-m1 by a twoand fourfold factor respectively. It is possible that a stabilization of Fra2 takes place in the v-Jun-transformed cells as a result of an excess of Jun(-like):Fra2 dimers which are more resistant to degradation. v-Jun might also activate transcription of the endogenous fra2 gene via Jun-binding sites present in the avian promoter (Sonobe et al., 1995; Muramaki et al., 1999) . Whatever the reason for this over-accumulation of Fra2, this observation reinforces the correlation between excess Fra2 and SPARC down-regulation.
In a second series of experiments with independently generated cultures, the eect of ATF2 was similarly tested. In contrast to Fra2, excess ATF2 alone had no signi®cant eect on SPARC mRNA and protein accumulation in non-transformed cells. However, it clearly alleviated the repression established by v-Jun(-m1). For instance, the steady-state levels of SPARC mRNA ( Figure 1c ) and protein ( Figure 1d ) were only weakly reduced by v-Jun(-m1)+ATF2. As found with Fra2, excess ATF2 did not change the accumulation of the v-Jun and v-Jun-m1 oncoproteins. It should be noted that in this second series of experiments the accumulation of ATF2 was not in¯uenced by v-Jun(-m1). This dierence in behaviour between Fra2 (see Figure 1b ;`anti-Fra2') and ATF2 (see Figure 1d ;`anti-ATF2') might re¯ect the fact that, in contrast to Fra2, ATF2 can form stable homodimers (Maekawa et al., 1989) and is therefore less dependent upon a dimerization partner for its maintenance.
Taken together, these data ®rst con®rmed that v-Jun and v-Jun-m1 repress the SPARC mRNA and protein Figure 1 Level of accumulation of the SPARC mRNA (by Northern blot analysis: a and c;), and of the SPARC, Jun, Fra2, and ATF2 proteins (by Western blot analysis; b and d). Extracts were from CEFs chronically infected by the empty vectors R and RD, or by Rcas vectors expressing v-Jun, v-Jun-m1(designated ml), Fra2, or ATF2, alone or in combination, as indicated. For Northern blot analysis, total RNA was probed with either the complete SPARC probe or a GAPDH probe. The arrows indicate the relevant transcripts. Western blotting was followed by detection of the accumulated proteins with speci®c antibodies using the ECL detection system. The arrows point to the various endogenous and exogenously expressed proteins. For instance the SPARC proteins are resolved into two closely migrating bands that are likely to correspond to two isoforms with distinct glycosylation levels (Vial and Castellazzi, 2000) . The Fra2 protein is present as several isoforms corresponding to distinct levels of phosphorylation present in CEFs (Muramaki et al., 1999; Sonobe et al., 1995) . The data shown in a and b, and c and d, were obtained from two independently generated series of cultures Oncogene Transcriptional control of SPARC by AP1 E Vial et al levels normally present in CEFs, to approximately 50% and 20%, respectively. Furthermore, they clearly indicated that the main dimerization partners of vJun exhibited antagonistic eects on SPARC downregulation by v-Jun and v-Jun-m1. Whereas Fra2 enhanced v-Jun-mediated repression, ATF2 alleviated the repression of SPARC by this oncoprotein.
To con®rm that the repression by v-Jun(-m1) was not due to a destabilization of the SPARC mRNA, and that it took place at the transcriptional level, the half-life of the transcript was compared in CEFs infected by R and R-v-Jun-m1. These cultures were treated for various times with actinomycin D, an inhibitor of mRNA synthesis. As shown in Figure 2 there was no detectable dierence in the steady-state level of the mRNA between the two extracts. This experiment also indicated that the SPARC message was extremely stable with a half-life of 38+2 h, a value which is in agreement with an independent study conducted in mammalian cells (Wrana et al., 1991) . These data led us to pursue the analysis of the repression by v-Jun at the level of an isolated fragment of the SPARC promoter.
Characterization of a minimal fragment (7124/+16) of the avian SPARC promoter that displays high basal activity and responds to repression by v-Jun A 1.6 kb fragment upstream of the SPARC coding sequence was isolated from a chicken genomic library. Figure 3 gives the complete sequence (a) as well as the results of a primer extension experiment for the localization of the main start-point of transcription (nucleotide+1; b). (Note the presence of an unusual stretch of eight GGA motifs covering the nucleotides 787 to 757 and designated the`GGA box' hereafter, as well as the lack of a TATA and CAAT box; see also Discussion.) A promoter fragment extending from nucleotide 71133 to +16 was then cloned in front of a luciferase reporter gene. Derivatives deleted for various 5' portions were also generated.
As shown in Figure 4 , the transcriptional activity of the largest 5' fragment of the SPARC gene was tested in transient transfection assays in R, R-v-Jun, and R-vJun-m1-infected CEFs. There was a strong basal activity in R-infected, non-transformed cultures (arbitrarily set at 100%; identical to the non-infected, nontransformed CEFs) that is consistent with the high amount of endogenous SPARC message in these cells. (Note that the Northern blots in Figure 1a ,c were made following very short exposures of less than 2 h.) In CEFs transformed by v-Jun and m1, this basal activity was reduced to 68 and 36% respectively. These residual levels were close to, although slightly higher than, those reported above for the endogenous mRNA (see Figure 1a ,c).
Interestingly, the deleted fragments 7664/+16 and 7124/+16 exhibited basal activities that were only slightly reduced in non-transformed CEFs (92 and 83% respectively). Shorter forms, 792/+16, and 778/ +16 whose deletion extended inside the GGA box, were less active. However, all these constructs retained an equally strong repression when transfected into vJun(-m1)-transformed CEFs. The shortest form, 756/ +16, lacking the purine-rich stretch did not show any detectable activity at all. This result is consistent with a previous observation showing that the purine-rich box from the human BM-40/SPARC gene promoter is essential for maximum basal transcription (Hafner et al., 1994) . Moreover, the requirement of an intact GGA box in the avian promoter for ecient basal transcription is further supported by the fact that the 7124 DGGA/+16 construct, containing an internal deletion covering the entire GGA box, was also totally inactive.
The activities of the large 71133/+16 and the small 7124/+16 constructs were then analysed in non- Taken together these data clearly show that the minimal 7124/+16 promoter displays the main features reported above for the endogenous gene, Figure 2 Stability of the SPARC mRNA in CEFs chronically infected by R or by R-v-Jun-m1 (designated ml). RNA was isolated from exponentially growing CEFs after treatment with 5 mg/ml actinomycin D for 0, 6, 9, 12 and 24 h. Northern blot of total RNA was probed with SPARC and GAPDH (upper panel). The ®gure represents the amount of SPARC mRNA relative to the amount of GAPDH after various times of treatment. In this particular experiment the steady-state level in ml-transformed CEFs is about 40% of the amount in non-transformed CEFs (set at 100%) Transcriptional control of SPARC by AP1 E Vial et al that is, (i) high basal activity, (ii) repression by v-Jun, and (iii) antagonistic eect by Fra2 and ATF2. Interestingly, the cultures transformed by v-Jun were the most sensitive to a change in the level of Fra2 and ATF2, suggesting that in these cells a fragile balance between these two v-Jun partners controls SPARC transcription. These conclusions were con®rmed in the experiment shown in Figure 5 in which the activity of the 7124/+16 promoter was assessed in normal CEFs that were co-transfected by v-Jun, or v-Jun-m1, and various amounts of either Fra2 (a) or ATF2 (b).
The proximal fragment (7124/+16) minimal SPARC promoter responds to AP1 family members in normal CEFs
Finally, we compared the activity of all the known members of the Jun, Fos, ATF, and Maf families in normal CEFs transfected with the small 7124/+16 SPARC promoter. These AP1 components are likely to participate in the control of SPARC expression during embryonic development and in adult tissues, for instance, during wound healing and neoplastic progression. As shown in Figure 6 , all Jun members exhibited a more or less strong repression (the m1 derivatives being more potent), as well as Fra2 and c-Fos. As expected, ATF2, the only member of the ATF family known in avian cells , was an activator.
We further compared the three`large Maf' proteins recently isolated in avian cells that are likely to contribute to the composition of the AP1 transcription factor (Karin et al., 1997; Motohashi et al., 1997) : cMaf (identical to v-Maf, and the only one to be highly oncogenic; Kataoka et al., 1993; Nishizawa et al., 1989) , MafA (Benkhelifa et al., 1998) , and MafB (Kataoka et al., 1994) . Surprisingly the three members of the Maf family behaved dierently. Whereas c-Maf acted as a potent repressor, and MafA repressed poorly, MafB was an activator. To examine whether c-Maf also repressed SPARC in c-Maf-transformed cultures, CEFs infected by R, R-c-Maf, R-v-Jun, and R-v-Jun-m1 were generated. As shown in Figure 7 , the steady-state level of the SPARC mRNA (a) and protein (b) was indeed strongly repressed by c-Maf. The repression by this oncoprotein was stronger than that exerted by v-Jun and even by m1. Finally, the minimal promoter was also clearly subjected to a repression in these c-Maf-transformed CEFs. These results strengthened the view that, in avian cells, (i) the 7124/+16 promoter constitutes a model promoter that reproduces the behaviour of the endogenous gene, and therefore (ii) should be a useful tool for the study of the transcriptional control of SPARC by the various AP1 components.
Discussion
In this paper we have shown that in v-Jun-transformed CEFs down-regulation of SPARC takes place primarily at the transcriptional level, with no signi®cant destabilization of the SPARC mRNA. This repression is exacerbated by excess Fra2 and antagonized by ATF2, suggesting that a balance between these main vJun partners contributes to a ®ne-tuning of SPARC transcription. Figure 4 Transfection analysis of chicken SPARC promoter deletion constructs in infected CEFs. Each panel gives results from a series of cultures generated from a single primary culture, and values are average values of at least two independent experiments, with each point in duplicate. In (a) CEFs stably infected by R, R-v-Jun and R-v-Jun-m1 (designated m1) were transfected with dierent SPARC deletion constructs. Strong basal activity in R-infected CEFs was set at 100. In (b) and (c) the small promoter construct 7124/+16 was transfected into CEFs that stably expressed the various combinations of v-Jun, Fra2, and ATF2, as indicated. As in (a) the values with R-infected CEFs were set at 100. As stated in the text, parallel experiments with the entire 71133/+16 construct gave results that were very close to those presented in (b) and (c)
The organization of the proximal portion of the avian SPARC promoter and the 5' portion of the mRNA (sense strand) displays the following characteristics: (i) no TATA and CAAT box; (ii) a single major transcriptional start-point; (ii) a purine-rich region with a core sequence of eight GGA direct repeats in a row; (iii) the presence of an Ets consensus motif; and (iv) a short ®rst exon. These features are remarkably well conserved in the SPARC genes of the cow (Young et al., 1989) , mouse (McVey et al., 1988; Nomura et al., 1989) , and man (Hafner et al., 1994) . In these three species, however, the purine-rich region does not contain such a homogeneous, short core of GGA but rather a mixture of GGGGA and GGA (Figure 8 ). The chicken, mouse, and human purine-rich stretches have been shown to be required for maximum basal transcription (Hafner et al., 1994; Ibaraki et al., 1993; Nomura et al., 1989; this paper) .
A 71133/+16 promoter fragment displays high basal activity when transfected into CEFs, and is subjected to repression by v-Jun and modulation by Fra2 and ATF2 to an extent identical to the endogenous SPARC gene. Over 80% of the basal activity is contained within a short, proximal 7124/ +16 fragment that contains the entire GGA-rich stretch and that also retains repression by v-Jun and modulation by Fra2 and ATF2. We consider that this minimal promoter reproduces the behaviour of the endogenous SPARC gene, and therefore constitutes a reliable model for subsequent studies of transcriptional regulation by AP1. For example, a comparison of the various members of the Jun, Fos, ATF, and Maf proteins isolated from chicken cells indicates that they Although individual AP1 components do not show a strict correlation between the level of repression and oncogenic potential, it is nevertheless tempting to speculate that a ®ne-tuning of SPARC expression by the various combinations of AP1 dimers participate in the neoplastic process. Indeed, it has been shown that (i) uncontrolled expression and qualitative change of any component of AP1 is potentially transforming (Suzuki et al., 1994) , and that (ii) tumor progression is associated both with SPARC up-regulation in human breast (Graham et al., 1997) and colorectal (Porte et al., 1995) cancers and in melanoma (Ledda et al., 1997) , and with SPARC down-regulation in ovarian carcinoma (Mok et al., 1996) .
Repression of SPARC by the mouse c-Jun has also been reported in rat embryo ®broblasts (REFs) (Kraemer et al., 1999; Mettouchi et al., 1994) . This observation, in addition to the high sequence homology between the avian and human proximal promoters (Figure 4) , prompted us to test whether c-Jun-mediated repression takes place within the 7120/+28 human promoter fragment which corresponds to the avian 7124/+16 short fragment. As shown in Figure 9 , this is indeed the case. A parallel study on the control of SPARC by AP1 conducted in REF cells should therefore be informative.
Computer analysis of the minimal promoter fragment did not reveal any potential TPA-responsive (TRE) or cAMP-responsive (CRE) Jun-binding site. In agreement with this observation, electrophoretic mobility shift assays with in vitro-synthesized v-Jun, Fra2, and ATF2 proteins and double-stranded oligonucleotide probes covering the entire 7124/+16 fragment did not detect any Jun-containing retarded band (data not shown). Similar experiments with nuclear extracts from CEFs overexpressing ATF2 or v-Jun-m1+Fra2 were also conducted. As expected from previous reports (Ungefroren et al., 1998; Kumar and Butler, 1997 ) a strong binding of SP1/SP3(-like) factors was detected on the GGA-rich probes (Vial, Galvani, Oliviero and Castellazzi; in preparation) . This situation suggests that v-Jun might control the activity of the SPARC promoter indirectly. Such an indirect transcriptional control by c-Jun has recently been reported for the cell cycle inhibitor p21 (Kardassis et al., 1999) , and for the extracellular matrix component thrombospondin-1 . The characterization of the SP1/SP3-containing protein complexes that bind to the 7124/+16 promoter region in vivo should help us to understand how SPARC is controlled by v-Jun and the other AP1 family members in CEF cells.
Materials and methods
Promoter constructs
A 110 bp, HindIII ± BglII restriction fragment of the 5' portion of the avian SPARC cDNA (plasmid pH-SPARCsig+; Vial and Castellazzi, 2000) has been used to screen a chicken genomic library made from the liver of an adult male Leghorn (EMBL 3 SP6/T7 vector; Clontech). A phage carrying a 9.9 kb insert was recovered, from which a 1.6 kb, BamHI ± EagI restriction fragment was found to hybridize to a 25-mer synthetic oligonucleotide (Genset, Paris, France) complementary to the uppermost 5' non coding SPARC sequence obtained by RACE (`rapid ampli®cation of cDNA ends' kit; Boehringer). This 1.6 kb fragment was cloned directionally into the pBSK derivative pH (Vial and Castellazzi, 2000) between the BamHI and NotI sites, and sequenced (Genbank accession number AJ 243178). The 5' portion of this sequence encompassing the initiation site for transcription, has been recloned as a BamHI ± BstNI fragment into pGL3 basic (Promega), in front of the reporter gene luciferase. This plasmid, designated pSPARC(71133/ +16)-luciferase and for simplicity 71133/+16, has been routinely used for functional studies of the promoter in transient transfections. The 71133/+16 fragment has also been recut at various internal positions using the restriction enzymes depicted in Figure 3 , and cloned into the same plasmid, pGL3 basic, to generate the 7664/+16 and 7124/ +16 deleted derivatives (Figure 4) . The shortest promoter fragments present in 792/+16, 778/+16, 756/+16, and 7124 DGGA/+16 were cloned into pGL3 basic as PCR products. Modi®cations in the various promoters were con®rmed by DNA sequencing (Genome Express, Grenoble, France).
Cell culture
Primary CEF cultures were prepared from 8-day-old virusfree, O line chicken embryos (Institute for Animal Health, Compton, Berks, UK) and grown in regular medium supplemented with 6% serum (Castellazzi et al., 1990) . Replication-competent retroviruses Rcas with two dierent envelope speci®cities, envA and envD (Hugues et al., 1987) , and designated R and RD respectively, were used to express v-Jun (Jurdic et al., 1995 ), v-Jun-m1, Fra2 (Huguier et al., 1998 van Dam et al., 1998) , ATF2 (Huguier et al., 1998), and c-Maf (Baguet and Castellazzi, unpublished) . Routinely, transfections with R (no insert), R-Fra2, or R-ATF2 plasmid DNAs were performed after the ®rst passage using the Fugene-6 transfection reagent (Roche), and viruses were allowed to spread throughout the entire population over the following week. Doubly infected cultures were then generated by superinfection of R-derivatives with culture supernatant from CEFs chronically infected by RD-derivatives (i.e. RD, RD-v-Jun or RD-m1), and allowed to grow one more week before analysis. The various primary cultures, transformed or not, exibited a limited life span of about 5 to 6 weeks in vitro, corresponding approximately to 40 ± 60 culture doublings.
Determination of the transcription start site by primer extension
A 19-mer single-stranded oligonucleotide (complementary to the +18/+36 fragment; Figure 3a ) was end-labeled with T4 polynucleotide kinase and [g-32 P]ATP. 12.5 pmoles of the labeled oligonucleotide was mixed with 0.5 mg polyA + RNA from non-transformed CEFs in 10 ml H 2 O, denatured for 2 min at 808C, chilled on ice, and diluted twice in a premixed reagent for ®rst-strand cDNA synthesis (5'/3' RACE kit; Boehringer). AMV reverse transcriptase was allowed to polymerise for 1 h at 558C. A dideoxy DNA sequencing reaction of a plasmid pH containing the 1.6 kb, genomic BamHI ± EagI restriction fragment was performed using the same unlabeled 19-mer oligonucleotide as a primer, and the T7 sequencing kit (Pharmacia). Final samples of the primer Figure 8 Alignment of the known proximal SPARC promoter regions from chicken (accession number AJ 243178; this paper), man (accession number X82259; Hafner et al., 1994) , mouse (accession number J0391; McVey et al., 1988) , and cow (accession number J04424; Young et al., 1989) . The following main features are highlighted: the avian GGA-rich region (boxed), the Ets consensus sequence (underlined), the +1 main start-point of transcription. For each species the complete sequence of the ®rst exon is presented. The length of the chicken ®rst intron starting at nucleotide +49 has not been determined. Arrows indicate the extremities of the chicken and human constructs used in this paper Figure 9 Transfection analysis of a large 71409/+28 and short 7120/+28 fragment of the human SPARC promoter in REFs in the presence or absence of c-Jun (mouse). The basal activity with REFs transfected by the large promoter was set at 100 extension and DNA sequencing reactions were run in parallel in a 6% polyacrylamide sequencing gel.
Northern blotting
Total RNA was extracted and analysed by Northern blotting as described (Vial and Castellazzi, 2000) .
Western blotting and antibodies
Preparation of cell extracts were performed as described Vial and Castellazzi, 2000) . Polyclonal rabbit antibodies raised against GST fusion proteins which recognize c/v-Jun, SPARC (Vial and Castellazzi, 2000) , ATF2 , Fra2, and c-Maf, were used to detect the corresponding proteins on the blotted nitrocellulose membranes. To raise anti-Fra2 and anti-cMaf antibodies, GST-Fra2 and GST-c-Maf fusion proteins were prepared from bacteria carrying the pGEX-4T3 plasmid as described in the`GST-gene fusion' kit (Pharmacia) (Baguet and Castellazzi; unpublished). Rabbits were immunized by repeated intradermal injections of the puri®ed protein following standard technique (Covalab, Lyon, France).
Transient transactivation assay in CEFs
Cells stably infected by the dierent combinations of retroviruses were seeded at a density of 4610 5 per 60 mm diameter plate in normal medium, and transfected 24 h later with 1 mg of SPARC promoter construct, along with 2 ml of Fugene-6 transfection reagent (Roche). Cell lysate was prepared 40 h after transfection and the luciferase activity was measured using the`luciferase assay system' (Promega). To normalize for transfection eciencies, independent plates from the dierent cultures were routinely transfected with 1 mg pRSV-b gal plasmid, a pBSK derivative in which the bgalactosidase enzyme was under the control of the Rous sarcoma virus 5' LTR. Plates were stained in order to individually vizualize and count the b-galactosidase expressor cells. To do this, plates were rinsed with phosphate buered saline (PBS), ®xed for 5 min with a mixture of 2% formaldehyde and 0.2% glutaraldehyde in PBS, again rinsed with PBS, and stained for 2 ± 3 h at 378C with a mixture of 1 mg/ml X-gal (5-bromo-4-chloro-3-indolyl b-D-galactopyranoside; Eurogentec), 4 mM MgCl 2 , 4 mM potassium hexacyanoferrate (II), and 4 mM potassium hexacyanoferrate (III) in PBS. The coding sequences of the various AP1 components were expressed from a Rous sarcoma virus LTR in a pDP expression vector (Jurdic et al., 1995) . Unless otherwise stated, 0.5 mg of each of these plasmids was transfected per plate.
Transient transactivation assay in REFs
Transient transfections into non-transformed, primary REFs were performed as previously described (Vandel et al., 1996) . 10 mg promoter plasmid and 5 mg expression vector pDP-cJun were used per plate. Abbreviations CEF(s), chicken embryo ®broblast(s); REF(s), rat embryo ®broblast(s); SPARC, secreted protein, acidic, and rich in cysteine; AP1, activating protein 1
